Baird Reiterates Buy Rating on Abbott Laboratories
Baird reaffirmed its buy rating on Abbott Laboratories, setting a $121 price target, a 33.11% upside from the current price.
Key Points
- Baird reiterated its buy rating on Abbott Laboratories (NYSE:ABT) with a $121 target on July 1, 2026.
- Baird's $121 price target implies 33.11% upside from Abbott Laboratories's ($ABT) current $90.90 share price.
- Shares of Abbott traded at approximately $90.9 on Wednesday, with a market cap of about $158 billion and a P/E ratio of 25.4.
- Other analysts, including Piper Sandler and Barclays, also maintain buy ratings, with targets ranging from $115 to $143.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Baird reiterated its buy rating on Abbott Laboratories (NYSE:ABT), setting a price target of $121. This reaffirmation by analyst David Rescott keeps the focus on Abbott's potential for growth.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Abbott Laboratories Stock Down 19.2%
Shares of NYSE:ABT traded near $90.9 on Wednesday. Abbott Laboratories, a leader in the healthcare sector, boasts a market cap of approximately $158 billion. The company's P/E ratio stands at 25.4, with a forward P/E of 15.0. Abbott's beta is a low 0.62, indicating less volatility compared to the broader market. The stock's 52-week range is between $81.97 and $137.49, with a 50-day moving average of $89.07 and a 200-day moving average of $112.42.
$ABT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Abbott Laboratories reported revenue of about $45.1 billion, showing a growth of 7.8%. Its earnings per share (EPS) is $3.57, with a net margin of 13.9% and a return on equity (ROE) of 12.3%. The company is expected to announce its next earnings on July 16, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories offers a dividend rate of $2.52 per share, translating to a yield of 2.78%. The company's dividend payout ratio is 67.2%, providing investors with a steady income stream.
Insider Buying and Selling at Abbott Laboratories
Recent insider transactions include a sale by Elizabeth Cushman, EVP, GC, and Secretary, who sold 560 shares at $94.12 on June 27, 2026. On the buying side, John Stratton acquired 2,000 shares at $86.82 on May 7, 2026, and Mary Moreland, Executive Vice President, bought 5,314 shares at $94.41 on April 28, 2026.
Analysts Set New Price Targets
On July 1, 2026, Baird initiated coverage on Abbott Laboratories with a buy rating and a $121 price target. Piper Sandler reiterated its buy rating with a $115 target on June 22, 2026. Barclays maintained a buy rating with a $143 target on April 20, 2026. The consensus among 24 analysts is a buy rating, with a mean price target of $116.54.
About Abbott Laboratories
Abbott Laboratories, headquartered in Abbott Park, Illinois, is a global healthcare company. It operates through segments like Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott offers a wide range of products, including generic pharmaceuticals, diagnostic systems, and medical devices for cardiovascular and diabetes care. Founded in 1888, the company is led by CEO Mr. Philip P. Boudreau and employs around 122,000 people.
Bottom Line
Baird's reiteration of a buy rating with a $121 target reflects confidence in Abbott Laboratories' growth prospects. With a strong market position and steady financial performance, Abbott remains a focal point for investors. As always, remember that analyst ratings are forward-looking opinions based on available data.
Get Abbott Laboratories alerts
New 13F filings, insider trades, and analyst moves on $ABT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.